The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.
The funding is being provided by the Flemish government's Agency for Innovation and Entrepreneurship to support the three-year development project.
OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.
The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.
The partners will use Biolidics' circulating tumor cell retrieval system to evaluate the cells' utility as biomarkers of patient response to cancer treatment.
The firm anticipates that point-of-care adoption may attract licensing deals from companies interested in adding the biomarkers to their large laboratory analyzers.
The in vitro diagnostic company said it would use the financing to commercialize its antibiotic susceptibility platform called Reveal.
The test is the first near-patient assay for M. genitalium, and can also guide treatment by detecting antibacterial resistance markers.
New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.
The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.
The firm said that its rapid point-of-care test enables immediate drug adjustments by measuring levels of clozapine, an antipsychotic drug, in a finger prick of blood.
The French metagenomic sequencing firm received funding from both historical and new investors, including debt financing from Norgine Ventures.
OncoCyte believes Razor's CLIA-validated lung cancer prognostic test will complement its in-development DetermaVu lung cancer detection assay.
The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
Clinical applications grew 11 percent driven by 34 percent growth in the molecular biology segment, including a 31 percent spike in FilmArray product sales.
The combined firm will be based in Gaithersburg, Maryland and will focus on infectious disease diagnostics and antimicrobial resistance prediction services.
Cytek said that the approval places the company on a path to offering a complete spectral flow cytometry solution — including instruments and reagents — to customers in China.
While microbiology has traditionally relied heavily on manual processes, most workflows can now be automated, and AI tools promise to streamline it further.
The firm said it anticipates using the loan proceeds to fund its pursuit of corporate priorities, including broadening its product portfolio and geographic reach.